AR012340A1 - 3,4-dihidro-2(1h)-quinazolinonas 4,4-disustituidas utiles como inhibidores de la transcriptasa inversa del hiv, composicion y kitfarmaceuticos que las contienen - Google Patents

3,4-dihidro-2(1h)-quinazolinonas 4,4-disustituidas utiles como inhibidores de la transcriptasa inversa del hiv, composicion y kitfarmaceuticos que las contienen

Info

Publication number
AR012340A1
AR012340A1 ARP980101558A ARP980101558A AR012340A1 AR 012340 A1 AR012340 A1 AR 012340A1 AR P980101558 A ARP980101558 A AR P980101558A AR P980101558 A ARP980101558 A AR P980101558A AR 012340 A1 AR012340 A1 AR 012340A1
Authority
AR
Argentina
Prior art keywords
substituted
dihydro
useful
nr5r5a
reverse transcriptase
Prior art date
Application number
ARP980101558A
Other languages
English (en)
Spanish (es)
Original Assignee
Du Pont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont filed Critical Du Pont
Publication of AR012340A1 publication Critical patent/AR012340A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP980101558A 1997-04-09 1998-04-06 3,4-dihidro-2(1h)-quinazolinonas 4,4-disustituidas utiles como inhibidores de la transcriptasa inversa del hiv, composicion y kitfarmaceuticos que las contienen AR012340A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83854097A 1997-04-09 1997-04-09
US7132298P 1998-01-14 1998-01-14

Publications (1)

Publication Number Publication Date
AR012340A1 true AR012340A1 (es) 2000-10-18

Family

ID=26752095

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980101558A AR012340A1 (es) 1997-04-09 1998-04-06 3,4-dihidro-2(1h)-quinazolinonas 4,4-disustituidas utiles como inhibidores de la transcriptasa inversa del hiv, composicion y kitfarmaceuticos que las contienen

Country Status (19)

Country Link
EP (1) EP0973753A2 (zh)
JP (1) JP2002504095A (zh)
KR (1) KR20010006146A (zh)
CN (1) CN1252063A (zh)
AR (1) AR012340A1 (zh)
AU (1) AU734928B2 (zh)
BR (1) BR9808513A (zh)
CA (1) CA2284996A1 (zh)
EA (1) EA001991B1 (zh)
EE (1) EE9900452A (zh)
HR (1) HRP980143A2 (zh)
HU (1) HUP0001446A3 (zh)
IL (1) IL132188A0 (zh)
NO (1) NO314936B1 (zh)
NZ (1) NZ500592A (zh)
PL (1) PL336305A1 (zh)
SK (1) SK137899A3 (zh)
TW (1) TW587078B (zh)
WO (1) WO1998045276A2 (zh)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999050253A1 (en) * 1998-03-27 1999-10-07 Du Pont Pharmaceuticals Company 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinthione derivatives, their preparation and their use as hiv reverse transcriptase inhibitors
WO2000021565A1 (en) 1998-10-13 2000-04-20 Du Pont Pharmaceuticals Company Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent
WO2000029390A1 (en) * 1998-11-19 2000-05-25 Du Pont Pharmaceuticals Company Crystalline (-)-6- chloro-4- cyclopropylethynyl- 4-trifluoromethyl- 3,4-dihydro- 2(1h)-quinazolinone
WO2000029391A1 (en) * 1998-11-19 2000-05-25 Du Pont Pharmaceuticals Company Process for the preparation of quinazolinones
US6175009B1 (en) 1999-11-18 2001-01-16 Dupont Pharmaceuticals Company Process for the preparation of quinazolinones
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
JP2003528043A (ja) 1999-11-23 2003-09-24 スミスクライン・ビーチャム・コーポレイション ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４‐ジヒドロ−（１Ｈ）キナゾリン−２−オン化合物
US6555686B2 (en) * 2000-03-23 2003-04-29 Bristol-Myers Squibb Pharma Asymmetric synthesis of quinazolin-2-ones useful as HIV reverse transcriptase inhibitors
AU2001249161A1 (en) * 2000-03-23 2001-10-03 Bristol-Myers Squibb Pharma Company Asymmetric synthesis of quinazolin-2-ones useful as hiv reverse transcriptase inhibitors
US6596729B2 (en) * 2000-07-20 2003-07-22 Bristol-Myers Squibb Company Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
ZA200300255B (en) 2000-07-20 2004-09-28 Bristol Myers Squibb Pharma Co Tricyclic 2-pyridone compounds useful as HIV reverse transcriptase inhibitors.
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7025774B2 (en) 2001-06-12 2006-04-11 Pelikan Technologies, Inc. Tissue penetration device
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7713214B2 (en) 2002-04-19 2010-05-11 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with optical analyte sensing
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
JP2006514045A (ja) * 2002-12-16 2006-04-27 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド チプラナビル及びカプラビリンの組み合せ投与によるｈｉｖ感染症の処置
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
US8282576B2 (en) 2003-09-29 2012-10-09 Sanofi-Aventis Deutschland Gmbh Method and apparatus for an improved sample capture device
US9351680B2 (en) 2003-10-14 2016-05-31 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a variable user interface
WO2005065414A2 (en) 2003-12-31 2005-07-21 Pelikan Technologies, Inc. Method and apparatus for improving fluidic flow and sample capture
EP1751546A2 (en) 2004-05-20 2007-02-14 Albatros Technologies GmbH & Co. KG Printable hydrogel for biosensors
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
EP1765194A4 (en) 2004-06-03 2010-09-29 Pelikan Technologies Inc METHOD AND APPARATUS FOR MANUFACTURING A DEVICE FOR SAMPLING LIQUIDS
EP2265324B1 (en) 2008-04-11 2015-01-28 Sanofi-Aventis Deutschland GmbH Integrated analyte measurement system
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
CN102060786A (zh) * 2011-01-20 2011-05-18 天津大学 4-(取代-1,3-二炔基)-4-(三氟甲基)-3,4-二氢取代喹唑啉-2-酮类化合物及其制备方法和应用
US9839684B2 (en) * 2011-04-06 2017-12-12 Biovaxim Limited Pharmaceutical compositions comprising inactivated HIV viral particles and non-pathogenic lactobacilli for the induction of antigen-specific immunotolerance
WO2013175417A1 (en) 2012-05-24 2013-11-28 Novartis Ag Pyrrolopyrrolidinone compounds
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
EP2948451B1 (en) 2013-01-22 2017-07-12 Novartis AG Substituted purinone compounds
JP6373978B2 (ja) 2013-05-27 2018-08-15 ノバルティス アーゲー イミダゾピロリジノン誘導体および疾患の処置におけるその使用
ES2650562T3 (es) 2013-05-28 2018-01-19 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades
ES2656471T3 (es) 2013-05-28 2018-02-27 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona como inhibidores de BET y su uso en el tratamiento de enfermedades
EP3071571A1 (en) 2013-11-21 2016-09-28 Novartis AG Pyrrolopyrrolone derivatives and their use as bet inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102764A0 (en) * 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
WO1993004047A1 (en) * 1991-08-16 1993-03-04 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
WO1993022292A1 (en) * 1992-05-07 1993-11-11 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
US5665720A (en) * 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
DE4320347A1 (de) * 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
GB2281297A (en) * 1993-08-27 1995-03-01 Merck & Co Inc Quinazoline compounds
AU1046895A (en) * 1993-11-05 1995-05-23 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
US5434152A (en) * 1993-11-08 1995-07-18 Merck & Co., Inc. Asymmetric synthesis of (S)-(-)-6-chloro-4- cyclopropyl-3,4-dihydro-4-[(2-pyridyl)ethynyl]-2(1H)-quinazolinone

Also Published As

Publication number Publication date
NO994904D0 (no) 1999-10-08
PL336305A1 (en) 2000-06-19
AU6796098A (en) 1998-10-30
EA199900907A1 (ru) 2000-04-24
BR9808513A (pt) 2000-05-23
CN1252063A (zh) 2000-05-03
SK137899A3 (en) 2000-05-16
EA001991B1 (ru) 2001-10-22
TW587078B (en) 2004-05-11
HUP0001446A3 (en) 2001-11-28
EE9900452A (et) 2000-04-17
WO1998045276A2 (en) 1998-10-15
AU734928B2 (en) 2001-06-28
HUP0001446A2 (hu) 2001-05-28
NO994904L (no) 1999-12-01
CA2284996A1 (en) 1998-10-15
KR20010006146A (ko) 2001-01-26
EP0973753A2 (en) 2000-01-26
WO1998045276A3 (en) 1999-01-14
JP2002504095A (ja) 2002-02-05
HRP980143A2 (en) 1999-02-28
IL132188A0 (en) 2001-03-19
NO314936B1 (no) 2003-06-16
NZ500592A (en) 2001-09-28

Similar Documents

Publication Publication Date Title
AR012340A1 (es) 3,4-dihidro-2(1h)-quinazolinonas 4,4-disustituidas utiles como inhibidores de la transcriptasa inversa del hiv, composicion y kitfarmaceuticos que las contienen
ECSP045229A (es) Piridinonas sustituidas como moduladores de la p38 map quinasa
PA8551001A1 (es) Nuevos compuestos
CO5600998A2 (es) Fluoropirrolidinas como inhibidores de dipeptidil peptidasa
HUP0203450A2 (hu) Pirazolo[4,3-d]pirimidin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ECSP055636A (es) Acidos tienil-hidroxamicos sustituidos, y su uso para tratar enfermedades asociadas con la actividad enzimatica de la histona desacetilasa
CO5580747A2 (es) Derivados e intermediarios de n-adamantilmetilo como composiciones farmaceuticas y procesos para su preparacion
AR055878A1 (es) Derivados de ciclopropanocarboxamida
BR0012646A (pt) Composto, análogo de oligonucleotìdeo ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um análogo de oligonucleotìdeo
AR071043A1 (es) Acido l -glutamico marcado con (f -18), l- glutamina marcada con (f-18), sus derivados y su uso, asi como procedimientos para su preparacion
ES2087721T3 (es) Guanidinas sustituidas con (benzodioxano, benzofurano o benzopirano)-alquilamino-alquilo como vasoconstrictores selectivos.
CR7956A (es) Oxazolidinonas de indolona antibacterial intermedios para su preparacion y composiciones farmaceuticas que contienen los mismos
AR012489A1 (es) Tiofenopiridinas antagonistas del factor de liberacion de corticotropina. procedimiento para su preparacion, el uso de las mismas en la preparacionde un medicamento, composicion farmaceutica que las comprende, procedimiento para la preparacion de dicha composicion, un compuesto intermediario y
CO5631434A2 (es) Derivados de piridina-carboxamida y su uso como plaguicidas
PE58599A1 (es) 2-amino-6-(4-fenoxi-2-sustituido)-piridinas sustituidas
AR031774A1 (es) Nuevos derivados de diaminopirazol y su utilizacion en tintura de oxidacion de las fibras queratinicas
PA8589801A1 (es) Aminoalcoxiindoles
PE20011349A1 (es) 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
CO5050264A1 (es) Derivados de 6-azauracilo como inhibidores il-5 procedimientos para su preparacion y composiciones farmaceuticas que comprenden dichos derivados
AR054418A1 (es) Quinazolinas pirazolamino sustituidas. procesos de obtencion y composiciones farmaceuticas.
AR052663A1 (es) Compuestos de oxima heterociclicos, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen
CL2021002475A1 (es) Formulaciones fungicidas con crecimiento reducido de cristales.
NO158256C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive trisubstituerte pyrimido(5,4-d)pyrimidiner.
RU2004130284A (ru) Антипаразитарные производные артемизинина (эндопероксиды)
AR001995A1 (es) Derivados de bencisoxazol, procedimientos para su manufactura, agentes antiparasitarios que los contienen como ingredientes activos y procedimientospara el control de microorganismos fitopatogenicos, insectos y acaros.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal